TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28506538

Group type: EXPERIMENTAL
Intervention: Nexvax2 60 μg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nexvax2 90 μg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nexvax2 150 μg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nexvax2 150 μg (biopsy cohort)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nexvax2 300 μg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (biopsy cohort)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nexvax2 150 μg (MTD)
Number of subjects: 108
Study: 26482674

Group type: EXPERIMENTAL
Intervention: HPV vaccine-specific brochure, telephone recalls to parents who declined, and recalls to patients overdue for doses 2 and 3
Number of subjects: 814

Group type: COMPARATOR
Intervention: General adolescent vaccine brochure (active comparison)
Number of subjects: 814
Study: 24429154

Group type: EXPERIMENTAL
Intervention: Nebulised MgSO(4) (three 500 mg doses in 1 h) alongside standard therapy
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Intravenous MgSO(4) (2 g in 20 min) alongside standard therapy
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Placebo control plus standard therapy alone
Number of subjects: 1109
Study: 20820175

Group type: EXPERIMENTAL
Intervention: Message frames about weight discrimination
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Control condition with no paragraph
Number of subjects: 1114
Study: 19953707

Group type: EXPERIMENTAL
Intervention: Lanreotide 30 mg PR
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 16714635

Group type: EXPERIMENTAL
Intervention: Patient-controlled room air (RA) insufflation
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Automated carbon dioxide (CO2) delivery
Number of subjects: 208

Group type: COMPARATOR
Intervention: Combined supine/prone assessment
Number of subjects: 208

Group type: COMPARATOR
Intervention: Colonic distention in supine position
Number of subjects: 208
Study: 15765277

Group type: EXPERIMENTAL
Intervention: Pheromone formula added to preferred fragrance
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 11320107

Group type: EXPERIMENTAL
Intervention: Intense strength training (77.8 +/- 3.4% of 1-repetition maximum) for 8 weeks, 3 days per week, two sets of 10 repetitions for six lower body exercises
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonintervention control
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intense strength training
Number of subjects: 24
Study: 9243684

Group type: EXPERIMENTAL
Intervention: Thiopentone induction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Halothane induction
Number of subjects: 100
Study: 7921994

Group type: EXPERIMENTAL
Intervention: Exogenously added stroma related factors such as kit ligand or IL-11
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of peripheral blood stem cells in autologous transplants
Number of subjects: 0
Study: 3727190

Group type: EXPERIMENTAL
Intervention: Pelvic floor training program (5 weekly lessons guided by trained physiotherapists)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 50
Study: 30689800

Group type: EXPERIMENTAL
Intervention: Reduced ticagrelor maintenance dose (60 mg b.i.d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard ticagrelor maintenance dose (90 mg b.i.d)
Number of subjects: 52
Study: 29214415

Group type: EXPERIMENTAL
Intervention: 5 days of filgrastim
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 7 days of filgrastim
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 10 days of filgrastim
Number of subjects: 142
Study: 26764156

Group type: EXPERIMENTAL
Intervention: Mavoglurant (25, 50, or 100 mg twice daily)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 25061127

Group type: EXPERIMENTAL
Intervention: Intradialytic cycling for 24 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pedometer program for 24 weeks
Number of subjects: 60
Study: 22545007

Group type: EXPERIMENTAL
Intervention: Monthly magazines and newsletters aimed at promotion of healthy eating
Number of subjects: 860

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 860
Study: 20832366

Group type: EXPERIMENTAL
Intervention: artesunate‐amodiaquine
Number of subjects: 827

Group type: COMPARATOR
Intervention: artemether‐lumefantrine
Number of subjects: 827

Group type: COMPARATOR
Intervention: fixed‐dose artesunate‐mefloquine
Number of subjects: 827

Group type: COMPARATOR
Intervention: loose artesunate‐mefloquine
Number of subjects: 827

Group type: COMPARATOR
Intervention: dihydroartemisinin‐piperaquine
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: primaquine (0.75 mg/kg)
Number of subjects: 827
Study: 18591401

Group type: EXPERIMENTAL
Intervention: Short-term hospitalization with diabetes education and support (STH)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Nonhospitalization but diabetes education and support (DES)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control group (neither hospitalization nor education)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Comparison between STH and DES
Number of subjects: 426
Study: 15748975

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation via formula containing 0.36% DHA and 0.72% ARA or human milk
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Breast-feeding duration
Number of subjects: 243
Study: 12420014

Group type: EXPERIMENTAL
Intervention: Intra-oral lubricating device
Number of subjects: 34
Study: 10474784

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study: 8621857

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2019665

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.2 mg/inh) followed by theophylline (130 mg) with ephedrine (24 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metaproterenol (0.65 mg/inh)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo inhaler and tablets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epinephrine and theophylline with ephedrine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7056196

Group type: EXPERIMENTAL
Intervention: human milk (1.6 g/100 kcal)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: formula 1 (2.3 g/100 kcal)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: formula 2 (3.0 g/100 kcal)
Number of subjects: 48

Group type: COMPARATOR
Intervention: formula (1.6 g/100 kcal, 2.3 g/100 kcal, 3.0 g/100 kcal)
Number of subjects: 48
Study: 30832681

Group type: EXPERIMENTAL
Intervention: Double-layer closure of the uterine incision
Number of subjects: 2290

Group type: COMPARATOR
Intervention: Single-layer closure of the uterine incision (control group)
Number of subjects: 2290
Study: 28460575

Group type: EXPERIMENTAL
Intervention: Low AGE diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High AGE diet
Number of subjects: 0
Study: 26710049

Group type: EXPERIMENTAL
Intervention: Laser Doppler imaging combined with clinical assessment
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard care (clinical assessment only)
Number of subjects: 202
Study: 25185149

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program (3 months, twice-weekly, 90-min exercise sessions, total 24 sessions)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (maintained normal physical activity)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (rehabilitation and control)
Number of subjects: 21
Study: 23265749

Group type: EXPERIMENTAL
Intervention: Quadriceps-sparing TKA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard medial parapatellar TKA
Number of subjects: 60
Study: 20137596

Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen 100 mg before surgery (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen 100 mg at the end of surgery (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 60
Study: 16685553

Group type: EXPERIMENTAL
Intervention: 48-week strength training, performed twice per week, consisting of three series of 10 repetitions of calf-rise at 75% of the 3-repetition maximum.
Number of subjects: 0
Study: 16019074

Group type: EXPERIMENTAL
Intervention: Betaxolol plus laser trabeculoplasty
Number of subjects: 255

Group type: COMPARATOR
Intervention: No initial treatment
Number of subjects: 255
Study: 12136369

Group type: EXPERIMENTAL
Intervention: Tezosentan (6.25 mg/h and 25 mg/h for 6 h) with cyclosporin (400 mg single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tezosentan (6.25 mg/h and 25 mg/h for 6 h) alone
Number of subjects: 12
Study: 10597779

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ZDV-ddC, ZDV-ddI, D4T-ddI, three-drug regimen)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Three-drug regimen (stavudine, lamivudine, ritonavir)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Three-drug regimen
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Two-drug groups
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Three-drug group
Number of subjects: 161
Study: 7472724

Group type: EXPERIMENTAL
Intervention: Behaviour rating scale
Number of subjects: 5

Group type: COMPARATOR
Intervention: Other four scales
Number of subjects: 5
Study: 1957876

Group type: EXPERIMENTAL
Intervention: Multiple choice question
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Dichotomous response format
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Oral communication channel
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Written communication channel
Number of subjects: 1078
Study: 7036281

Group type: COMPARATOR
Intervention: LMF plus BCG (six cycles of Leukeran plus methotrexate plus fluorouracil plus repeated BCG skin scarifications)
Number of subjects: 242

Group type: COMPARATOR
Intervention: LMF plus BCG
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: LMF plus BCG (greater than 90% of planned LMF dose)
Number of subjects: 242

Group type: COMPARATOR
Intervention: LMF alone (nonrandomized comparison)
Number of subjects: 242
Study: 29150789

Group type: EXPERIMENTAL
Intervention: Cold Stress (CS) - immersion in 15 °C water for 5 min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Heat Stress (HS) - immersion in 40 °C water for 5 min
Number of subjects: 60
Study: 29410081

Group type: EXPERIMENTAL
Intervention: α-blockade preoperatively
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Pre-stented patients
Number of subjects: 135
Study: 26418143

Group type: EXPERIMENTAL
Intervention: 1470-nm laser ablation (10 W, continuous mode)
Number of subjects: 67

Group type: COMPARATOR
Intervention: 1920-nm laser ablation (5 W)
Number of subjects: 67
Study: 25047374

Group type: EXPERIMENTAL
Intervention: ToyBox-intervention (multi-component, kindergarten-based, family-involved intervention)
Number of subjects: 7056

Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 7056
Study: 22562783

Group type: EXPERIMENTAL
Intervention: Fixed combination of moxifloxacin 0.5%/dexamethasone 0.1% ophthalmic solution
Number of subjects: 102

Group type: COMPARATOR
Intervention: Moxifloxacin 0.5% ophthalmic solution and dexamethasone 0.1% (concomitant group)
Number of subjects: 102
Study: 20730641

Group type: EXPERIMENTAL
Intervention: Mothers and Toddlers Program (MTP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Parent Education Program (PE)
Number of subjects: 47
Study: 18642781

Group type: EXPERIMENTAL
Intervention: Predictive ocular saccade in PD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Random ocular saccade in PD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Predictive saccades in PD patients
Number of subjects: 24
Study: 16372388

Group type: EXPERIMENTAL
Intervention: P-splines based model for ERPs curves with random effects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical strategies for ERP analysis
Number of subjects: 0
Study: 14641923

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg, t.d.s.)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (t.d.s.)
Number of subjects: 32
Study: 10965102

Group type: EXPERIMENTAL
Intervention: Ondansentron 8 mg every 8 hours with dexamethasone 8 mg before cisplatin infusion and continued after 8 and 16 hours.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ondansentron 8 mg every 6 hours with dexamethasone 8 mg before cisplatin infusion and continued after 6, 12, and 18 hours.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups received a total dose of 24 mg ondansentron during the acute phase of emesis.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control for nausea and vomiting episodes.
Number of subjects: 100
Study: 9102051

Group type: EXPERIMENTAL
Intervention: Gamma nail osteosynthesis
Number of subjects: 222

Group type: COMPARATOR
Intervention: Former osteosynthesis techniques
Number of subjects: 222
Study: 1795315

Group type: EXPERIMENTAL
Intervention: Combination of mineral baths and mud packs (Group 1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Tap water baths only (Group 2)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Mineral baths and mud packs (for osteoarthritis patients)
Number of subjects: 53
Study: 6225751

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg bw
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg bw
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg bw
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Sebum suppression
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Subjective side effects
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Triglycerides and cholesterol
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Laboratory parameters
Number of subjects: 198
Study: 31177143

Group type: EXPERIMENTAL
Intervention: Image-guided brachytherapy (IGBT)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Conventional two-dimensional brachytherapy (2DBT)
Number of subjects: 253
Study: 28399840

Group type: EXPERIMENTAL
Intervention: Endoscopic transanal proctectomy (ETAP)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Laparoscopic proctectomy (LAP)
Number of subjects: 226
Study: 25464463

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (30 s at 100% of max workload, followed by 30 s at rest, 45 min 3 days/week for 12 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study: 25619045

Group type: EXPERIMENTAL
Intervention: Intra-articular sodium hyaluronate (1%; 2,2-2,7 MDa), administered once weekly for 3 weeks (3 injections)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Symptomatic slow-acting drugs for osteoarthritis (SYSADOA)
Number of subjects: 75
Study: 22349603

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) at 6 weeks after surgery
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no ESWT)
Number of subjects: 71
Study: 19754679

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Epsilon‐aminocaproic acid (Amicar)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Aprotinin and Epsilon‐aminocaproic acid (Amicar)
Number of subjects: 39
Study: 17668086

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching agents (3M Zaris, 3M Espe; Nite White Excel, Discus Dental)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nontreated teeth
Number of subjects: 10
Study: 15150563

Group type: EXPERIMENTAL
Intervention: AUC group (Calvert's formula, AUC set at 4.5)
Number of subjects: 28

Group type: COMPARATOR
Intervention: BS group (Body Surface area calculation)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AUC group (Calvert's formula)
Number of subjects: 28
Study: 11493236

Group type: EXPERIMENTAL
Intervention: Alfentanil-morphine mixture (0.75 : 10 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 58
Study: 9808867

Group type: EXPERIMENTAL
Intervention: Cyclosporine A levels > 3 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HMG-CoA-reductase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies for blocking T-cell costimulation and expression of adhesion molecules, cytokines and antiendothelial antibodies, antiproliferative drugs, methods to augment endogenous nitric oxide bioavailability, newer immunosuppressive regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revascularization procedures
Number of subjects: 0
Study: 8048813

Group type: EXPERIMENTAL
Intervention: Inexpensive measuring instruments
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Experienced observers
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Inexperienced observers
Number of subjects: 26

Group type: COMPARATOR
Intervention: Expensive measuring instruments
Number of subjects: 26
Study: 3181646

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (4.0 g omega-3 fatty acids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (7.5 g omega-3 fatty acids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Safflower oil (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 0
Study: 30264906

Group type: EXPERIMENTAL
Intervention: Condition 3 (15 min sitting interrupted by 3-min light-intensity walking breaks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Condition 1 (7 h sitting interrupted every 60 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Condition 2 (7 h sitting interrupted every 30 min)
Number of subjects: 12
Study: 27056846

Group type: EXPERIMENTAL
Intervention: MAXout treatment (18-week treatment, two 90-minute sessions per week)
Number of subjects: 0
Study: 25828740

Group type: EXPERIMENTAL
Intervention: Postconditioning (postcon)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional PCI (control)
Number of subjects: 75
Study: 23297321

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Physiologic saline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Iomeprol
Number of subjects: 120

Group type: COMPARATOR
Intervention: N-acetylcysteine, sodium bicarbonate, or physiologic saline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NGAL
Number of subjects: 120
Study: 21884868

Group type: EXPERIMENTAL
Intervention: Verbal suggestion (VS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 19407804

Group type: EXPERIMENTAL
Intervention: Verapamil SR-based antihypertensive treatment
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Atenolol-based antihypertensive treatment
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Control group (genotype T/T, T/C, C/C)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Both treatment groups (Verapamil and Atenolol)
Number of subjects: 1025
Study: 16731300

Group type: EXPERIMENTAL
Intervention: Standard efficiency acetate-free biofiltration (AFB) for 4 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher efficiency acetate-free biofiltration (AFB) for 4 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-hour acetate-free biofiltration (AFB) session
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-hour acetate-free biofiltration (AFB) session
Number of subjects: 0
Study: 15126313

Group type: EXPERIMENTAL
Intervention: Active treatment to eradicate H pylori infection
Number of subjects: 10537

Group type: EXPERIMENTAL
Intervention: H pylori infection
Number of subjects: 10537
Study: 11273059

Group type: EXPERIMENTAL
Intervention: Banked breastmilk
Number of subjects: 216

Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard term formula
Number of subjects: 216
Study: 9781431

Group type: EXPERIMENTAL
Intervention: Sparfloxacin 200 mg administered 1 hour before urethrocystoscopy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg administered 1 hour before urethrocystography
Number of subjects: 78

Group type: COMPARATOR
Intervention: No antibiotic (control group) for both procedures
Number of subjects: 78
Study: 7823492

Group type: EXPERIMENTAL
Intervention: Radionuclide investigation
Number of subjects: 122
Study: 3244560

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (4 mg.kg b.w.‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29355361

Group type: EXPERIMENTAL
Intervention: Enhanced consultation/coaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard consultation
Number of subjects: 0
Study: 28956934

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Spirit-only MI (SOMI)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Nontherapy control condition
Number of subjects: 139
Study: 26096115

Group type: EXPERIMENTAL
Intervention: Laser excision
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scalpel excision
Number of subjects: 20
Study: 22930491

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR) plus treatment as usual (TAU)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Completer analyses (≥ 4 classes attended)
Number of subjects: 47
Study: 22027737

Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus‐eluting stent
Number of subjects: 80

Group type: COMPARATOR
Intervention: Coroflex Blue postdilated with the paclitaxel-eluting balloon Sequent Please
Number of subjects: 80
Study: 18454988

Group type: EXPERIMENTAL
Intervention: Early steroid reduction (G1; n = 31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular steroid dosage maintenance (G2; n = 29)
Number of subjects: 60
Study: 17159691

Group type: EXPERIMENTAL
Intervention: Trochanteric fixation nail (TFN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 60